Bahls M, Lorenz MW, Dörr M, Gao L, Kitagawa K, Tuomainen TP, Agewall S, Berenson G, Catapano AL, Norata GD, Bots ML, van Gilst W, Asselbergs FW, Brouwers FP, Uthoff H, Sander D, Poppert H, Hecht Olsen M, Empana JP, Schminke U, Baldassarre D, Veglia F, Franco OH, Kavousi M, de Groot E et al. (2019)
Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium
Eur J Prev Cardiol, 2047487319877078 (in press)
DOI 10.1177/2047487319877078, PubMed 31619084

Windecker S, Lopes RD, Massaro T, Jones-Burton C, Granger CB, Aronson R, Heizer G, Goodman SG, Darius H, Jones WS, Aschermann M, Brieger D, Cura F, Engstrøm T, Fridrich V, Halvorsen S, Huber K, Kang HJ, Leiva-Pons JL, Lewis BS, Malaga G, Meneveau N, Merkely B, Milicic D, Morais J et al. (2019)
Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights from the AUGUSTUS Trial
Circulation (in press)
DOI 10.1161/CIRCULATIONAHA.119.043308, PubMed 31557056

Agewall S (2019)
European Heart Journal - Cardiovascular Pharmacotherapy has received its first Impact Factor of 6.723
Eur Heart J Cardiovasc Pharmacother, 5 (4), 183-184
DOI 10.1093/ehjcvp/pvz041, PubMed 31531677